Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Langleben, A. M. Hirsch, E. Shalit, L. Lesenko, R. J. Barst (Montreal, Canada; New York, United States Of America). Sustained efficacy with the selective endothelin-A receptor antagonist, sitaxsentan, after two years of therapy in patients with pulmonary arterial hypertension. Eur Respir J 2005; 26: Suppl. 49, 1334

Member's Comments

No comment yet.

Related content which might interest you: Successful transition from oral prostacyclin analogue (beraprost) to the selective endothelin receptor antagonist (sitaxsentan) therapy in pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment Year: 2007 Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2004; 24: 1007-1010 Year: 2004 Goal-oriented treatment and combination therapy for pulmonary arterial hypertension Source: Eur Respir J 2005; 26: 858-863 Year: 2005 Survival with first-line bosentan in patients with primary pulmonary hypertension Source: Eur Respir J 2005; 25: 244-249 Year: 2005 Dual endothelin receptor antagonism: setting standards in PAH Source: Eur Respir Rev 2008; 17: 13-18 Year: 2007 Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment Source: Eur Respir J 2011; 38: 851-860 Year: 2011 The use of combination therapy in pulmonary arterial hypertension: new developments Source: Eur Respir Rev 2009; 18: 148-153 Year: 2009 Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006 Oct 01;28(4):691-694 Year: 2006 Endothelin receptor antagonists in pulmonary arterial hypertension Source: Eur Respir J 2008; 31: 407-415 Year: 2008 Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 Source: Eur Respir J 2004; 24: 353-359 Year: 2004 Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy Source: Eur Respir J 2005; 26: Suppl. 49, 476s Year: 2005 Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension}, Source: Eur Respir J 2012; 40: 874-880 Year: 2012 Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy Source: Eur Respir Rev 2009; 18: 253-259 Year: 2009 Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure Source: Eur Respir J 2011; 37: 578-586 Year: 2011 Bosentan therapy for portopulmonary hypertension Source: Eur Respir J 2005; 25: 502-508 Year: 2005 Switch of patients with pulmonary arterial hypertension after withdrawal of the endothelin receptor antagonist sitaxentan Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Endothelin: setting the scene in PAH Source: Eur Respir Rev 2008; 17: 3-7 Year: 2007 Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 92-98 Year: 2009 Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension Source: Eur Respir J 2013; 41: 96-103 Year: 2013 Peripheral airway dysfunction persist after endothelin receptor antagonist therapy in patients with idiopathic pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary circulation Year: 2009